Revumenib
Syndax Pharma
['revumenib', 'leusm', 'augment,trial', 'augment,data', 'hydroxyurea', 'augment-101', 'augment,study', 'leukemia', 'sndx-5613']
congress | #ash22
ghavas issa of presents data from augment-101 phase i trial of the menin-kmt2a interaction inhibitor revumenib (sndx-5613) in r/r acute leukemia, including patients with kmt2ar or npm1 mutations.
#leusm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm